IL17A and psoriasis: Some authors suggest that, in patients with psoriasis and chronic or previous hepatitis B infection, the first choice should be the use of anti-IL17, followed by anti-IL23; however, the evidence to support this recommendation is scarce and more studies are needed to support it.72